BDSX Share Price Performance
US$14.37
6.47 (81.85%)
52.1% undervalued intrinsic discount
US$30.00
Fair Value
Price US$14.37
AnalystConsensusTarget US$30.00
AnalystHighTarget US$40.00
AnalystLowTarget US$20.00
Fair ValueUS$30.00
Share Pricen/a
Biodesix, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
BDSX Community Narratives
AN
Fair Value
·Fair Value US$30 52.1% undervalued intrinsic discount
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$40 64.1% undervalued intrinsic discount
Precision Medicine And AI Will Fuel Diagnostic Evolution
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$20 28.2% undervalued intrinsic discount
Lung Diagnostics Will Face Regulatory Delays While Modest Progress Unfolds
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Precision Medicine And AI Will Fuel Diagnostic Evolution
Key Takeaways Expanding access to primary care and rapid clinical validation position Biodesix for outsized revenue growth, improved margins, and accelerated payer coverage, boosting profitability and cash flow. Integration of multi-omics, AI, and digital tools along with strong pharma partnerships drive platform dominance, recurring revenues, and sustained long-term earnings expansion.Read more
AN
US$40
64.1% undervalued intrinsic discount
Fair Value
Profit Margin
5.1%
Future PE
73.88x
Price in 2029
US$48.68
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
Key Takeaways Expanded sales structure and digital adoption are driving higher test volumes, improved efficiency, customer retention, and recurring revenues while lowering administrative costs. Clinical validation, payer coverage efforts, and development services growth support broader market adoption, revenue diversification, and increased long-term financial stability.Read more
AN
US$30
52.1% undervalued intrinsic discount
Fair Value
Profit Margin
5.12%
Future PE
57.47x
Price in 2029
US$36.49
Lung Diagnostics Will Face Regulatory Delays While Modest Progress Unfolds
Key Takeaways Operational and reimbursement hurdles may restrict revenue growth and margin expansion despite efforts to widen adoption and capitalize on innovative diagnostic trends. Competitive threats and shifting technology demands require sustained investment, raising compliance and R&D costs while heightening risks to long-term profitability.Read more
AN
US$20
28.2% undervalued intrinsic discount
Fair Value
Profit Margin
5.58%
Future PE
34.31x
Price in 2029
US$24.33
Trending Discussion
Recently Updated Narratives
AN
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Fair Value: US$40 64.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Fair Value: US$30 52.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Fair Value: US$20 28.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biodesix, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -3.16
- 81.66%
- -33.26%
- 509.1%
About BDSX
- Founded
- 2005
- Employees
- 334
- CEO
- WebsiteView website
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
